興科蓉醫藥(06833.HK):成都天府國際生物城管理委員會將協助公司於醫美產品領域建立產業化基地
格隆匯1月6日丨興科蓉醫藥(06833.HK)公吿,公司已於2022年1月6日收到成都天府國際生物城管理委員會的函件。於該函件中,委員會表示其全力支持公司的智能醫美產業園項目及其對聚己內酯等醫美產品的研究及發展和產業化,委員會將為公司醫美產業園項目及上述醫美產品的研究及發展和產業化提供良好的營商環境、優質高效的政務服務,並在資源和人才方面給予支持及保證。此外,委員會表示其將協助公司於醫美產品領域建立重要研究及發展策源地及產業化基地,並已設立專項工作小組協調有關實施醫美產業園項目事宜及日常聯絡工作。
公司將就成都醫美產業園項目與委員會及相關政府機關積極合作,並與其磋商政府支援計劃的詳情。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.